Cargando…

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Young Kwang, Arya, Ayush, Iams, Wade, Cruz, Marcelo R., Chandra, Sunandana, Choi, Jaehyuk, Giles, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/
https://www.ncbi.nlm.nih.gov/pubmed/29769148
http://dx.doi.org/10.1186/s40425-018-0349-3
_version_ 1783323964776382464
author Chae, Young Kwang
Arya, Ayush
Iams, Wade
Cruz, Marcelo R.
Chandra, Sunandana
Choi, Jaehyuk
Giles, Francis
author_facet Chae, Young Kwang
Arya, Ayush
Iams, Wade
Cruz, Marcelo R.
Chandra, Sunandana
Choi, Jaehyuk
Giles, Francis
author_sort Chae, Young Kwang
collection PubMed
description Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies.
format Online
Article
Text
id pubmed-5956851
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59568512018-05-24 Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC) Chae, Young Kwang Arya, Ayush Iams, Wade Cruz, Marcelo R. Chandra, Sunandana Choi, Jaehyuk Giles, Francis J Immunother Cancer Review Immunotherapy is among the most rapidly evolving treatment strategies in oncology. The therapeutic potential of immune-checkpoint inhibitors is exemplified by the recent hail of Food and Drug Administration (FDA) approvals for their use in various malignancies. Continued efforts to enhance outcomes with immunotherapy agents have led to the formulation of advanced treatment strategies. Recent evidence from pre-clinical studies evaluating immune-checkpoint inhibitors in various cancer cell-lines has suggested that combinatorial approaches may have superior survival outcomes compared to single-agent immunotherapy regimens. Preliminary trials assessing combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 immune-checkpoint inhibitors have documented considerable advantages in survival indices over single-agent immunotherapy. The therapeutic potential of combinatorial approaches is highlighted by the recent FDA approval of nivolumab plus ipilimumab for patients with advanced melanoma. Presently, dual-immune checkpoint inhibition with anti-programmed death receptor-1/programmed cell death receptor- ligand-1 (anti-PD-1/PD-L1) plus anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) monoclonal antibodies (MoAbs) is being evaluated for a wide range of tumor histologies. Furthermore, several ongoing clinical trials are investigating combination checkpoint inhibition in association with traditional treatment modalities such as chemotherapy, surgery, and radiation. In this review, we summarize the current landscape of combination therapy with anti-PD-1/PD-L1 plus anti-CTLA-4 MoAbs for patients with melanoma and non-small cell lung cancer (NSCLC). We present a synopsis of the prospects for expanding the indications of dual immune-checkpoint inhibition therapy to a more diverse set of tumor histologies. BioMed Central 2018-05-16 /pmc/articles/PMC5956851/ /pubmed/29769148 http://dx.doi.org/10.1186/s40425-018-0349-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Chae, Young Kwang
Arya, Ayush
Iams, Wade
Cruz, Marcelo R.
Chandra, Sunandana
Choi, Jaehyuk
Giles, Francis
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title_full Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title_fullStr Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title_full_unstemmed Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title_short Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
title_sort current landscape and future of dual anti-ctla4 and pd-1/pd-l1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (nsclc)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956851/
https://www.ncbi.nlm.nih.gov/pubmed/29769148
http://dx.doi.org/10.1186/s40425-018-0349-3
work_keys_str_mv AT chaeyoungkwang currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT aryaayush currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT iamswade currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT cruzmarcelor currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT chandrasunandana currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT choijaehyuk currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc
AT gilesfrancis currentlandscapeandfutureofdualantictla4andpd1pdl1blockadeimmunotherapyincancerlessonslearnedfromclinicaltrialswithmelanomaandnonsmallcelllungcancernsclc